Respiratory syncytial virus vaccine (GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRespiratory syncytial virus vaccine (GlaxoSmithKline)

Drug Alias NameN/A

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Live attenuated vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsRespiratory Syncytial Virus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc +[2]

Active IndicationsN/A

Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A